Trial Profile

RASolute 305: A Phase 3 randomized, double-blind, placebo-controlled, registrational trial evaluating zoldonrasib in combination with investigator's choice of either gemcitabine nab-paclitaxel or modified FOLFIRINOX compared to investigator's choice of the chemotherapies in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) harboring KRAS G12D mutation

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zoldonrasib (Primary) ; Fluorouracil+Folinic acid+Irinotecan+Oxaliplatin; Gemcitabine; Paclitaxel
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Registrational; Therapeutic Use
Acronyms RASolute 305
Sponsors REVOLUTION Medicines

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com